From: Moving toward a contemporary classification of drug-induced kidney disease
Type of damage | Examples |
---|---|
Glomerular/vascular | |
Minimal change disease | Interferon alpha & beta, Lithium |
Focal segmental glomerulosclerosis | Bisphosphonates (especially pamidronate and zoledronic acid), Lithium |
Membranous nephropathy | Penicillamine, Anti-tumor necrosis factor agents |
Vasculitis | Hydralazine, Propylthiouracil, Allopurinol, Phenytoin, Penicillamine, Minocycline |
Thrombotic microangiopathy | Gemcitabine, Bevacizumab, Interferon alpha, Ticlopidine, Clopidogrel, Oral contraceptives |
Cholesterol emboli | Warfarin, Streptokinase, Alteplase |
Tubular | |
Acute tubular injury/necrosis | Aminoglycosides, Vancomycin, Colistin, Foscarnet, Pentamidine, Tenofovir, Cisplatin, Carboplatin, Zoledronic acid |
Fanconi syndrome | Tenofovir, Sodium valproate, Deferasirox |
Obstructive nephropathy | Acyclovir, Sulfonamides, Methotrexate, Indinavir, Atazanavir, Triamterene, Sodium phosphate |
Rhabdomyolysis | Lovastatin, Simvastatin |
Tumor lysis syndrome | Cytotoxic agents, Glucocorticoids |
Osmotic nephrosis | Intravenous immunoglobulin, Hydroxyethyl starch |
Nephrogenic diabetes insipidus | Lithium |
Nephrogenic syndrome of inappropriate antidiuresis | Carbamazepine, Haloperidol, Cyclophosphamide, Selective serotonin reuptake inhibitors |
Interstitial | |
Acute tubulointerstitial nephritis | Beta-lactam antibiotics, Rifampin, Aminosalicylates, Proton pump inhibitors |
Chronic tubulointerstitial nephritis | Lithium, Aristolochic Acid |